FDA Rejects Claritin-Singulair (Loratadine-Montelukast) Combo Allergy Drug

The U.S. Food and Drug Administration rejected a proposed asthma-allergy medication that would have combined two best-selling drugs, Claritin (left) and Singulair (right), into one tablet by Schering-Plough and Merck. The companies received a "not-approvable" letter from the FDA for the combination product.

Claritin, one of the best-selling drugs ever, is now sold generically, while Singulair is still covered by patents.

References:

FDA rejects Schering-Merck combo allergy drug. The Guardian.
Images source: Wikipedia, public domain.